India, April 12 -- AbbVie (ABBV) reported promising results from the Phase 2 IMGN853-0420 trial evaluating mirvetuximab soravtansine-gynx (ELAHERE) in combination with carboplatin, followed by mirvetuximab soravtansine monotherapy. In patients with platinum-sensitive ovarian cancer (PSOC) who had =50% folate receptor alpha (FRa) expression, the regimen achieved an objective response rate of 62.7%. Importantly, the safety profile remained consistent with prior findings, underscoring the tolerability of this antibody-drug conjugate approach.
These findings highlight the potential of mirvetuximab soravtansine across the ovarian cancer treatment continuum, particularly in FRa-positive populations where targeted therapy can make a meaningful im...